A Study to Assess the Safety, Tolerability, and Immunogenicity of 3 Lots of a Multivalent Pneumococcal Conjugate Vaccine Administered to Adults
A PHASE 3, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF 3 LOTS OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS
The purpose of this study is to provide safety data and demonstrate lot consistency with the PG4 vaccine by evaluating the immunogenicity of 3 different lots of this vaccine.
This study will compare a new pneumococcal vaccine with the vaccine currently in use to see if they are similarly safe. It will also compare three batches of the new vaccine to make sure they work the same way. Blood samples will be taken to measure how the body responds to the vaccines.
The study will be conducted in the United States. Participants will be assigned to 1 of 4 groups. Group 1: PG4 vaccine lot 1; Group 2: PG4 vaccine lot 2; Group 3: PG4 vaccine lot 3; Group 4: 20vPnC.
Within each group, participants will be assigned by chance in a 2:2:2:1 ratio to receive 1 vaccine injection (shot) with either PG4 (new vaccine) lot 1, PG4 lot 2, PG4 Lot 3 or 20vPnC, given in the arm. This means that for every 7 participants, about 2 will receive either PG4 lot 1, lot 2 or lot 3 and about 1 will receive 20vPnC.
Each participant will take part in the study for approximately 6 months.
Studie Overzicht
Toestand
Toestand
Conditie
Conditie
Interventie / Behandeling
Interventie / Behandeling
Studietype
Studietype
Inschrijving (Werkelijk)
Inschrijving
Fase
Fase
- Fase 3
Contacten en locaties
Studie Locaties
-
-
Alabama
-
Birmingham, Alabama, Verenigde Staten, 35216
- Achieve Clinical Research, LLC d/b/a Accel Research Sites - Birmingham Clinical Research Unit
-
-
California
-
Lake Forest, California, Verenigde Staten, 92630
- Orange County Research Center
-
Walnut Creek, California, Verenigde Staten, 94598
- Diablo Clinical Research, LLC dba Flourish Research
-
-
Connecticut
-
Milford, Connecticut, Verenigde Staten, 06460
- Clinical Research Consulting
-
-
Florida
-
Doral, Florida, Verenigde Staten, 33172
- Suncoast Research Associates
-
Hollywood, Florida, Verenigde Staten, 33024
- Research Centers of America
-
Jacksonville, Florida, Verenigde Staten, 32216
- East Coast Institute for Research, LLC
-
Miami, Florida, Verenigde Staten, 33176
- Entrust Clinical Research
-
Miami Lakes, Florida, Verenigde Staten, 33014
- Palm Springs Community Health Center
-
Miami Lakes, Florida, Verenigde Staten, 33016
- Indago Research and Health Center, Inc.
-
Palmetto Bay, Florida, Verenigde Staten, 33157
- Innovation Medical Research, LLC
-
West Palm Beach, Florida, Verenigde Staten, 33409
- Palm Beach Research Center
-
-
Georgia
-
Fayetteville, Georgia, Verenigde Staten, 30214
- Javara Inc.
-
Stockbridge, Georgia, Verenigde Staten, 30281
- Clinical Research Atlanta
-
-
Hawaii
-
Honolulu, Hawaii, Verenigde Staten, 96814
- East-West Medical Research Institute
-
-
Illinois
-
Melrose Park, Illinois, Verenigde Staten, 60160
- DM Clinical Research
-
-
Iowa
-
Sioux City, Iowa, Verenigde Staten, 51106
- Velocity Clinical Research, Sioux City
-
-
Michigan
-
Grosse Pointe Woods, Michigan, Verenigde Staten, 48236
- Henry Ford St. John Hospital - Thomas Mackey Center for Infectious Disease Research
-
-
Missouri
-
Chesterfield, Missouri, Verenigde Staten, 63005
- Clinical Research Professionals
-
Springfield, Missouri, Verenigde Staten, 65802
- Bio-Kinetic Clinical Applications, LLC dba QPS-MO
-
Springfield, Missouri, Verenigde Staten, 65807
- Bio-Kinetic Clinical Applications, LLC dba QPS-MO-Screening and Recruitment Center
-
St Louis, Missouri, Verenigde Staten, 63141
- Sundance Clinical Research, LLC
-
-
Nebraska
-
Grand Island, Nebraska, Verenigde Staten, 68803
- Velocity Clinical Research, Grand Island
-
-
New Jersey
-
Somers Point, New Jersey, Verenigde Staten, 08244
- South Jersey Infectious Disease
-
-
North Carolina
-
Wilmington, North Carolina, Verenigde Staten, 28401
- Accellacare - Wilmington
-
-
Ohio
-
Cincinnati, Ohio, Verenigde Staten, 45212
- CTI Clinical Research Center
-
Cincinnati, Ohio, Verenigde Staten, 45206
- Cincinnati Children's Hospital Medical Center Vaccine Research Center
-
Cincinnati, Ohio, Verenigde Staten, 45206
- Cincinnati Children's Hospital Medical Center Investigational Drug Services
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Verenigde Staten, 19107
- DM Clinical Research
-
-
South Carolina
-
Moncks Corner, South Carolina, Verenigde Staten, 29461
- Clinical Trials of South Carolina
-
Myrtle Beach, South Carolina, Verenigde Staten, 29572
- TMA Headlands LLC (d/b/a Trial Management Associates)
-
North Charleston, South Carolina, Verenigde Staten, 29405
- Coastal Carolina Research Center, LLC
-
-
Texas
-
Mesquite, Texas, Verenigde Staten, 75149
- SMS Clinical Research LLC
-
Sugar Land, Texas, Verenigde Staten, 77478
- DM Clinical Research - Sugar Land
-
Tomball, Texas, Verenigde Staten, 77375
- DM Clinical Research
-
-
Utah
-
Salt Lake City, Utah, Verenigde Staten, 84109
- J. Lewis Research, Inc. / Foothill Family Clinic
-
Salt Lake City, Utah, Verenigde Staten, 84121
- J. Lewis Research, Inc. / Foothill Family Clinic South
-
-
Deelname Criteria
Geschiktheidscriteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
Adults 18 through 49 years of age, who have no history of receiving a pneumococcal vaccine after 5 years of age.
Exclusion Criteria:
Individuals with a history of severe allergic reactions to a vaccine or its components, serious chronic medical disorders, significant psychiatric conditions, known or suspected immunodeficiency, substance abuse issues, asplenia, bleeding diathesis or prolonged bleeding, a history of a prior confirmed invasive pneumococcal infection, and pregnant or breastfeeding females will be excluded from enrollment in the trial.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Preventie
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Verdrievoudigen
Aantal wapens
Wapens en interventies
Deelnemersgroep / ArmDeelnemersgroep / Arm |
Interventie / BehandelingInterventie / Behandeling |
|---|---|
|
Experimenteel: PG4 Vaccine Lot 3
Multivalent Pneumococcal Vaccine |
Multivalent Pneumococcal Vaccine
Andere namen:
|
|
Experimenteel: PG4 Vaccine Lot 2
Multivalent Pneumococcal Vaccine |
Multivalent Pneumococcal Vaccine
Andere namen:
|
|
Experimenteel: PG4 Vaccine Lot 1
Multivalent Pneumococcal Vaccine |
Multivalent Pneumococcal Vaccine
Andere namen:
|
|
Actieve vergelijker: 20 Valent Pneumococcal Conjugate Vaccine (20vPnC)
20 Valent Pneumococcal Conjugate Vaccine |
20 Valent Pneumococcal Conjugate Vaccine
Andere namen:
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Percentage of Participants with Prespecified Local Reactions Within 7 Days After Vaccination
Tijdsspanne: Within 7 days after Vaccination
|
Prompted local reactions after each dose |
Within 7 days after Vaccination
|
|
Percentage of Participants reporting Prespecified Systemic Events Within 7 Days after Vaccination
Tijdsspanne: Within 7 days after Vaccination
|
Prompted systemic events after each dose |
Within 7 days after Vaccination
|
|
Percentage of Participants with Adverse Events (AEs)
Tijdsspanne: From Vaccination to 1 month after Vaccination
|
AEs occurring from Dose 1 to 1 month after the vaccination |
From Vaccination to 1 month after Vaccination
|
|
Percentage of Participants with Serious Adverse Events (SAEs)
Tijdsspanne: From Vaccination to 6 months after Vaccination
|
SAEs occurring from Dose 1 to 6 months after the vaccination |
From Vaccination to 6 months after Vaccination
|
|
OPA geometric mean ratios (GMR) between each pair of PG4 vaccine lots
Tijdsspanne: 1 month after Vaccination
|
OPA GMRs between each pair of PG4 vaccine lots at 1 month after vaccination |
1 month after Vaccination
|
Secundaire uitkomstmaten
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
OPA Serotype-specific geometric mean titers (GMT) for PG4 vaccine serotypes
Tijdsspanne: 1 month after Vaccination
|
OPA GMTs at 1 month after vaccination |
1 month after Vaccination
|
|
OPA geometric mean fold rise (GMFR) for PG4 vaccine serotypes
Tijdsspanne: From before vaccination to 1 month after vaccination
|
GMFRs in OPA titers from before to 1 month after vaccination |
From before vaccination to 1 month after vaccination
|
|
Percentages of participants with a ≥4-fold rise in opsonophagocytic activity (OPA) titers
Tijdsspanne: From Vaccination to 6 months after Vaccination
|
Percentages of participants with a ≥4-fold rise in OPA titers from before to 1 month after vaccination |
From Vaccination to 6 months after Vaccination
|
|
Percentages of participants with OPA titers ≥ lower limit of quantitation (LLOQ)
Tijdsspanne: From before vaccination to 1 month after vaccination
|
Percentages of participants with OPA titers ≥ lower limit of quantitation (LLOQ) from before vaccination to 1 month after vaccination |
From before vaccination to 1 month after vaccination
|
Medewerkers en onderzoekers
Sponsor
Sponsor
Onderzoekers
Onderzoekers
- Studie directeur: Pfizer CT.gov Call Center, Pfizer
Publicaties en nuttige links
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Studie start
Primaire voltooiing (Geschat)
Primaire voltooiing
Studie voltooiing (Geschat)
Studie voltooiing
Studieregistratiedata
Eerst ingediend
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Eerst geplaatst
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update geplaatst
Laatste update ingediend die voldeed aan QC-criteria
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
Andere studie-ID-nummers
- C4931012
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .